<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289194</url>
  </required_header>
  <id_info>
    <org_study_id>ALICELL-CT-01</org_study_id>
    <secondary_id>2019-002688-89</secondary_id>
    <nct_id>NCT04289194</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Phase 1/2 Clinical Study to Assess the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of HCR040, Allogeneic Adipose-derived Adult Mesenchymal Stem Cells, in Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Histocell, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Histocell, S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to assess the feasibility, safety, and tolerability of the&#xD;
      administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived&#xD;
      adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute&#xD;
      respiratory distress syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCR040 is an investigational medicinal product whose active substance is HC016, allogeneic&#xD;
      adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.&#xD;
&#xD;
      The main purpose of this study is to evaluate the safety and tolerability of a single&#xD;
      administration of HCR040 using: a) two sequential escalating doses administered 96 hours&#xD;
      post-injury to participants with moderate to severe acute respiratory distress syndrome&#xD;
      (ARDS); and b) the determined maximum tolerated dose administered 96 hours post-injury to&#xD;
      participants with moderate to severe ARDS. The study also includes initial exploration of&#xD;
      efficacy.&#xD;
&#xD;
      Treatment is administered by intravenous injection.&#xD;
&#xD;
      The study has been divided into two phases:&#xD;
&#xD;
      Phase 1 (open label): 6 participants with moderate to severe ARDS will be included in 2&#xD;
      sequential cohorts.&#xD;
&#xD;
      Phase 2 (randomized, controlled, double-blind): 20 participants with moderate to severe ARDS&#xD;
      will be randomly divided into two groups (control and treated).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">April 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
    <description>SOFA index from 0 to 4 where lower scores represent improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation-free days 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent mortality 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pulmonary mechanics values (Ppl, DP, CRS)</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
    <description>Murray scale from 0 to 4 where lower scores represent improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days 28 days after the administration of HCR040</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>HCR040 (Phase 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate to severe acute respiratory distress syndrome (6 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Phase 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with moderate to severe acute respiratory distress syndrome (10 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCR040 (Phase 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate to severe acute respiratory distress syndrome (10 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCR040 (Phase 1)</intervention_name>
    <description>(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)</description>
    <arm_group_label>HCR040 (Phase 1)</arm_group_label>
    <other_name>Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Phase 2)</intervention_name>
    <description>(Phase 2) Intravenous administration of vehicle solution</description>
    <arm_group_label>Control group (Phase 2)</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCR040 (Phase 2)</intervention_name>
    <description>(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)</description>
    <arm_group_label>HCR040 (Phase 2)</arm_group_label>
    <other_name>Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥ 18 years&#xD;
&#xD;
          -  Patients with criteria of moderate to severe ARDS according to the Berlin Conference.&#xD;
&#xD;
          -  Berlin criteria of moderate to severe ARDS given simultaneously during the 24 hours&#xD;
             prior to entry into the study&#xD;
&#xD;
          -  Patients with invasive mechanical ventilation in controlled mode (VC, PC or VCRP)&#xD;
             adjusted to Vt≤8 mL/kg, Ppl &lt;30 cmH2O and minimum PEEP of 8 cmH2O&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a previous clinical study within 28 days prior to the ARDS situation&#xD;
&#xD;
          -  Administration of a previous cell therapy product in the 5 years prior to this ARDS&#xD;
             clinical situation&#xD;
&#xD;
          -  Inability to obtain Informed Consent&#xD;
&#xD;
          -  Hemodynamic instability that contraindicates the intravenous cellular administration,&#xD;
             within the defined time frame for inclusion in the study&#xD;
&#xD;
          -  Alveolar hemorrhage or hemoptysis&#xD;
&#xD;
          -  LTSV situation (Limitation of life support treatments)&#xD;
&#xD;
          -  Major trauma in the previous 5 days&#xD;
&#xD;
          -  Neoplastic processes at any time&#xD;
&#xD;
          -  EPOC or severe home asthma or any other type of chronic respiratory disease requiring&#xD;
             respiratory oxygen&#xD;
&#xD;
          -  Known Child-Pugh liver disease score &gt; B9&#xD;
&#xD;
          -  Pregnant women or women of childbearing age who are not using an adequate method of&#xD;
             contraception, or who, if they are using it, are not willing to continue using it for&#xD;
             the duration of the trial. If the patient is menopausal or sterile, it must be&#xD;
             documented in the medical record&#xD;
&#xD;
          -  Women who are breastfeeding if unwillingly to stop at the time of recruitment&#xD;
&#xD;
          -  Pulmonary transplant&#xD;
&#xD;
          -  Known grade III or IV pulmonary hypertension&#xD;
&#xD;
          -  States of hypercoagulability&#xD;
&#xD;
          -  History of DVP or PE in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fermin Labayen Beraza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Cruces</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Begoña Castro, PhD</last_name>
    <phone>+34 94 656 7900</phone>
    <email>bcastro@histocell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fermin Labayen Beraza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fermin Labayen Beraza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Serna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Boado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomás Muñoz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>anti-inflammation</keyword>
  <keyword>allogenic</keyword>
  <keyword>ARDS</keyword>
  <keyword>acute lung injury</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrogen Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

